Atopic DermatitisPhase 3AdoringNCT07265479
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
A Phase 3 study testing Tapinarof cream, 1% in people with Atopic Dermatitis, run by Organon and Co at 46 sites in 2 countries.
Trial summary
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis. Read more about this study
- Who is it for?
- Ages 3 to 23 months
- Conditions the study is for
- Atopic Dermatitis
- What is being tested?
- Tapinarof cream, 1%
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 187 participants
- Where
- 46 sitesin 2 countries
- Study dates
- 29 Dec 2025to Aug 2027
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 23 months
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to <24 months of age at the Screening visit.
- Clinical diagnosis of atopic dermatitis (AD), AD covering >5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
- Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities
- Legal guardian or primary caregiver is able and willing to adhere to protocol requirements
Who cannot join
- Significant neurological disorder or history of seizure
- Know clinically significant cardiac rhythm or cardiac disorder
- History of sudden infant death in a sibling
- Clinically significant chromosome abnormality
- History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
- Diseases that could cause pruritic and/or sleep disruption
Show all 10Show fewer
- Immunocompromised
- Current chronic or acute infection requiring treatment
- Use of prohibited medication(s) or procedure(s)
- Use of prohibited medications by breastfeeding mother if breastfeeding participant
Trial locations and contacts
46 sites in 2 countries.
46 sites in 2 countries
United States36 sites
Oakland Hills Dermatology
Auburn Hills, Michigan, 48326
The University of Texas Health Science Center at Houston
Bellaire, Texas, 77401
AllerVie Clinical Research
Birmingham, Alabama, 35209
Skin Care Research, LLC.
Boca Raton, Florida, 33486
Equity Medical, LLC
Bowling Green, Kentucky, 42104
Dermatology Trial Associates
Bryant, Arkansas, 72022
Clarity Dermatology
Castle Rock, Colorado, 80109
The University of North Carolina Dermatology and Skin Cancer Center
Chapel Hill, North Carolina, 27516
Medical University of South Carolina
Charleston, South Carolina, 29425
Cleaver Medical Group Dermatology, Inc
Cumming, Georgia, 30040
Dermatology Treatment and Research Center
Dallas, Texas, 75230
Dermatologists of Central States, LLC
Fairborn, Ohio, 45324
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, 46250
APEX Clinical Trials
Jacksonville, Florida, 32256
Forest Hills Dermatology Group
Kew Gardens, New York, 11415
Dermatology Research Associates
Los Angeles, California, 90045
Ada West Research
Meridian, Idaho, 83646
Minnesota Clinical Study Center
New Brighton, Minnesota, 55112
Bobby Buka MD, PC
New York, New York, 10012
National Allergy and Asthma Research, LLC.
North Charleston, South Carolina, 29420
Allergy Asthma and Clinical Research Center
Oklahoma City, Oklahoma, 73120
The Indiana Clinical Trials Center, PC
Plainfield, Indiana, 46168
Oregon Dermatology and Research Center
Portland, Oregon, 97210
Oregon Health & Science University
Portland, Oregon, 97239
Skin Cancer and Dermatology Institute
Reno, Nevada, 89509
SKY Integrative Medical Center
Ridgeland, Mississippi, 39157
Lawrence J Green, MD LLC
Rockville, Maryland, 20850
Integrative Skin Science and Research
Sacramento, California, 95815
MediSearch Clinical Trials
Saint Joseph, Missouri, 64506
Allergy and Asthma Medical Group and Research Center
San Diego, California, 92123
Endeavor Health Clinical Trials Center
Skokie, Illinois, 60077
Stryde Research - Epiphany Dermatology
Southlake, Texas, 76092
Dermatology Specialists of Spokane
Spokane, Washington, 99202
Equity Medical, LLC
The Bronx, New York, 10455
Clinical Trials Research Institute
Thousand Oaks, California, 91320
TruDerm Research
Wellington, Florida, 33449
Canada10 sites
Halton Pediatric Allergy
Burlington, Ontario, L7L 6W6
Dermatology Research Institute
Calgary, Alberta, T2J 7E1
Maritime Dermatology
Halifax, Nova Scotia, B3K 5R3
Triple A Lab Inc.
Hamilton, Ontario, L8S 1G5
Allergy Research Canada Inc.
Niagara Falls, Ontario, L2H 1C4
CARe Clinic (Central Alberta Research Clinic)
Red Deer, Alberta, T4P 1K4
Dr. Rachel Asiniwasis Medical Professional Corporation
Regina, Saskatchewan, S4V 1R9
Skinsense Medical Research
Saskatoon, Saskatchewan, S7K 2C1
Dr. Chih-Ho Hong Medical Inc.
Surrey, British Columbia, V3R 6A7
Manitoba Allergy Research Inc.
Winnipeg, Manitoba, R3J 0S9
About this study
Official title: A Randomized, Double-Blind, Vehicle-Controlled (Period 1) and Open-Label (Period 2) Phase 3 Study to Investigate the Safety and Efficacy of Tapinarof Cream, 1% in Pediatric Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
- Conditions
- Atopic Dermatitis
- Being tested
- Tapinarof cream, 1%, Vehicle Cream
- Keywords
- Pediatric Atopic Dermatitis, Eczema, tapinarof, topical
- Medical subject headings
- Dermatitis, Atopic, Eczema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tapinarof cream, 1%Drug
Also called OG-0505, DMVT-505, GSK2894512A, GSK28994512
Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.
Vehicle CreamDrug
Applied topically once daily to lesions on participant's skin during the Double-Blind period.
| Study group | Role | What they receive |
|---|---|---|
| Tapinarof cream | Experimental | Tapinarof cream, 1%, applied topically once daily Receives: Drug: Tapinarof cream, 1% |
| Vehicle cream | Placebo comparator | Vehicle cream is applied topically once daily for up to 8-weeks. Receives: Drug: Vehicle Cream |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8
The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.
Measured: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label Period
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint.. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.
Measured: Baseline to the end of the Open-Label Period, up to 56 weeks.
Secondary outcomes (11)
Percentage of participants with ≥ 75% improvement in Eczema Area and Severity Index (EASI) Score from Baseline to Week 8.
The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the %BSA affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. A higher EASI score represents more severe disease.
Measured: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Mean change in percentage of total body surface area (%BSA) affected from Baseline to Week 8
Assessment of %BSA is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% [10 handprints], upper extremities = 20% [20 handprints], trunk (including axillae and groin) = 30% [30 handprints], lower extremities, including buttocks, = 40% [40 handprints]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.
Measured: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Percentage of participants with ≥ 90% improvement in Eczema Area and Severity Index (EASI) score from Baseline to Week 8
Severity Index (EASI) score from Baseline to Week 8 Description: The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease.
Measured: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
TEAEs are AEs that started on or after the first dose of study medication.
Measured: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
TEAEs are AEs that started on or after the first dose of study medication.
Measured: Baseline to the end of the Open-Label Period, up to 56 weeks
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
TEAEs are AEs that started on or after the first dose of study medication.
Measured: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
TEAEs are AEs that started on or after the first dose of study medication.
Measured: Baseline to the end of the Open-Label Period, up to 56 weeks.
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.
Measured: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.
Measured: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.
Measured: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.
Measured: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2025
- Study start29 Dec 2025
- Primary completionAug 2027 (estimated)
- Study completionAug 2027 (estimated)
Why it stopped: As a precaution, study drug dosing is paused due to a PK finding in OG505-3104. No safety signal or change to the established safety or benefit-risk profile has been identified. The Sponsor is further investigating and assessing the data.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atopic DermatitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Following a screening period of up to 30 days, eligible participants will be randomly assigned to one of two groups for up to 8 weeks. During this time-called the Double-Blind Period-2 out of 3 participants will receive the active treatment (tapinarof cream, 1%), while 1 out of 3 will receive a vehicle cream (placebo). Following completion of the Double-blind period, participants will enter the 48-week Open Label Period and will be treated as needed.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 187 participants (actual)
Sponsor and investigators
- Lead sponsor
- Organon and Co
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Lead Late-Stage Clinical Development, Study director, Organon and Co
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07265479
- Sponsor's protocol ID
- OG0505-3104
- Acronym
- Adoring
- Status last verified
- Aug 2026
- First submitted
- 21 Nov 2025
- Last updated
- 5 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Vehicle-Controlled (Period 1) and Open-Label (Period 2) Phase 3 Study to Investigate the Safety and Efficacy of Tapinarof Cream, 1% in Pediatric Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
- ClinicalTrials.gov ID
- NCT07265479
- Acronym / sponsor ID
- Adoring / OG0505-3104
- Conditions
- Atopic Dermatitis
- Keywords
- Pediatric Atopic Dermatitis, Eczema, tapinarof, topical
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- SuspendedReason stopped: As a precaution, study drug dosing is paused due to a PK finding in OG505-3104. No safety signal or change to the established safety or benefit-risk profile has been identified. The Sponsor is further investigating and assessing the data.
- Enrolment
- 187 participants (actual)
- Lead sponsor
- Organon and CoIndustry (pharma, biotech, devices)
- Study start
- 29 Dec 2025 (actual)
- Primary completion
- Aug 2027 (estimated)
- Study completion
- Aug 2027 (estimated)
- First posted
- 4 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Following a screening period of up to 30 days, eligible participants will be randomly assigned to one of two groups for up to 8 weeks. During this time-called the Double-Blind Period-2 out of 3 participants will receive the active treatment (tapinarof cream, 1%), while 1 out of 3 will receive a vehicle cream (placebo). Following completion of the Double-blind period, participants will enter the 48-week Open Label Period and will be treated as needed.
| Arm | Type | Receives |
|---|---|---|
| Tapinarof cream | Experimental | Drug: Tapinarof cream, 1%Tapinarof cream, 1%, applied topically once daily |
| Vehicle cream | Placebo comparator | Drug: Vehicle CreamVehicle cream is applied topically once daily for up to 8-weeks. |
Who may qualify
- Ages
- 3 to 23 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to <24 months of age at the Screening visit.
- Clinical diagnosis of atopic dermatitis (AD), AD covering >5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
- Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities
- Legal guardian or primary caregiver is able and willing to adhere to protocol requirements
Key exclusion criteria (10 listed)
- Significant neurological disorder or history of seizure
- Know clinically significant cardiac rhythm or cardiac disorder
- History of sudden infant death in a sibling
- Clinically significant chromosome abnormality
- History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tapinarof cream, 1%Also: OG-0505, DMVT-505, GSK2894512A, GSK28994512Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed. | Drug | Tapinarof cream |
| Vehicle CreamApplied topically once daily to lesions on participant's skin during the Double-Blind period. | Drug | Vehicle cream |
Primary outcome
Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8
Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.
Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label Period
Time frame: Baseline to the end of the Open-Label Period, up to 56 weeks.
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint.. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.
11 secondary outcomes
Percentage of participants with ≥ 75% improvement in Eczema Area and Severity Index (EASI) Score from Baseline to Week 8.
Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Mean change in percentage of total body surface area (%BSA) affected from Baseline to Week 8
Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Percentage of participants with ≥ 90% improvement in Eczema Area and Severity Index (EASI) score from Baseline to Week 8
Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Time frame: Baseline to the end of the Open-Label Period, up to 56 weeks
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Time frame: Baseline to the end of the Open-Label Period, up to 56 weeks.
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Time frame: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Time frame: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Atopic Dermatitis
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Dermatitis Atopic
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Lead Late-Stage Clinical Development study director
Organon and Co
46 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Tapinarof cream, 1% in people with Atopic Dermatitis, run by Organon and Co at 46 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: paused, as of the sponsor's last update on 5 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 46 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8 (time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2026.